WHO suggest the cardiovascular disease (CVD) as the number 1 cause of death globally. Great advances have been made in identifying important markers for CVD. Implementing these in clinical practices can enhance the early diagnosis and better treatment of heart diseases. Newly identified biomarkers are GlycA and C-Reactive protein (CRP): Glycoproteins of acute‐phase reactants may be useful for the detection, prognosis, and therapeutic monitoring of tissue damage marked by inflammation.
GlycA is a marker of inflammation measured by nuclear magnetic resonance (NMR) spectroscopy that has been shown to be associated with cardiometabolic disease and mortality. Similarly, CRP is a blood marker produced by the liver in response to inflammation. High CRP levels can indicate that there is inflammation in the arteries of the heart, which can mean a higher risk for heart attack. New research…
